Vyndaqel has been approved by the European Commission and is expected to be launched in the EU in early 2012. Vyndaqel has also been awarded orphan drug designation in the US. Image courtesy of Pfizer.
-
Vyndaqel works by preventing mutation of TTR proteins and formation of... -
FAP is a hereditary disease caused by a mutation of the TTR gene. -
Vyndaqel has been approved by the European Commission.
